{"organizations": [], "uuid": "bfa9ef53348d2d9ed19a290bf12efffc9379a042", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ptc-therapeutics-announces-present/brief-ptc-therapeutics-announces-presentation-of-preliminary-data-from-part-1dose-finding-portion-of-ongoing-firefish-clinical-trial-idUSASC09X7H", "country": "US", "domain_rank": 408, "title": "BRIEF-PTC Therapeutics announces presentation of preliminary data from Part 1,dose finding portion, of ongoing FIREFISH clinical trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-25T04:52:00.000+03:00", "replies_count": 0, "uuid": "bfa9ef53348d2d9ed19a290bf12efffc9379a042"}, "author": "", "url": "https://www.reuters.com/article/brief-ptc-therapeutics-announces-present/brief-ptc-therapeutics-announces-presentation-of-preliminary-data-from-part-1dose-finding-portion-of-ongoing-firefish-clinical-trial-idUSASC09X7H", "ord_in_thread": 0, "title": "BRIEF-PTC Therapeutics announces presentation of preliminary data from Part 1,dose finding portion, of ongoing FIREFISH clinical trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-ptc therapeutics", "sentiment": "negative"}, {"name": "ptc therapeutics inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " PTC Therapeutics Inc:\n* PRELIMINARY CLINICAL DATA FROM FIREFISH TRIAL IN TYPE 1 SMA PATIENTS PRESENTED AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING\n* DATA FROM PART 1 DEMONSTRATED RG7916 HAS BEEN WELL TOLERATED AT ALL DOSE LEVELS Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-25T04:52:00.000+03:00", "crawled": "2018-04-25T05:10:51.011+03:00", "highlightTitle": ""}